SCHEMBL1615470

SCHEMBL1615470

c1cncc(COc2cccc3nc(NC4CCc5ccccc54)ccc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.49
HTR1A P08908 2/20 0.40
DRD2 P14416 1/20 0.40
EGFR P00533 1/20 0.40
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
P2RX7 Q99572 2/20 0.39
PFKFB3 Q16875 1/20 0.38
MGLL Q99685 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
IKBKB O14920 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
CD274 Q9NZQ7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615467 1.00 GBA1 (0.49) GBA1HTR1ADRD2EGFRJAK2
SCHEMBL1616465 0.86 MAOA (0.44) GBA1HTR1AEGFRP2RX7PFKFB3
SCHEMBL1616740 0.84 EGFR (0.47) HTR1ADRD2EGFRP2RX7PFKFB3
SCHEMBL1616738 0.84 EGFR (0.47) HTR1ADRD2EGFRP2RX7PFKFB3
SCHEMBL1616589 0.82 GBA1 (0.50) GBA1EGFRJAK2JAK3ALDH1A1
SCHEMBL3403513 0.81 CSF1R (0.47) GBA1JAK2JAK3PFKFB3CYP3A4
SCHEMBL4106156 0.81 CSF1R (0.47) GBA1JAK2JAK3PFKFB3CYP3A4
SCHEMBL2243055 0.80 NCF1 (0.49) GBA1EGFRP2RX7PFKFB3MAOB
SCHEMBL2243064 0.80 NCF1 (0.49) GBA1EGFRP2RX7PFKFB3MAOB
SCHEMBL2241645 0.79 PFKFB3 (0.54) GBA1EGFRP2RX7PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US claimed
EP-2099763-B1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-08-11 EP claimed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US claimed
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2099763-B1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146567-A1 QUINOLINES HTR5A, HTR2B, HTR2C GBA1 662/4885HTR1A 4/4885DRD2 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.